Background/Aim: Immune checkpoint inhibitors (ICIs) have an important role in lung cancer
therapy. Although the programmed cell death protein-1 (PD-L1) tumor proportion score (TPS…

Background For simultaneous prediction of phenotypic drug susceptibility test (pDST) for
multiple antituberculosis drugs, the whole genome sequencing (WGS) data can be analyzed …

Data from China have shown that the ratio of Mycobacterium tuberculosis-specific antigen (TBAg)
spots obtained from the T-SPOT.TB test to the number of positive control …

Background Advanced non‐small cell lung cancer (NSCLC) has a high mortality rate and
poor prognosis. However, outcomes have gradually improved after the introduction of novel …

Background Pembrolizumab alone or in combination with chemotherapy is a standard
treatment for patients with non‐small‐cell lung cancer (NSCLC) with high programmed death‐…

Background Differences in the resistance mechanisms of epidermal growth factor receptor
tyrosine kinase inhibitors in patients with non‐small cell lung cancer (NSCLC) harboring …

Background: Immune checkpoint inhibitors (ICIs) have shown remarkable therapeutic outcomes
among cancer patients. Durvalumab plus tremelimumab (DT) is under investigation as a …

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are extensively
used in the treatment of non-small cell lung cancer (NSCLC); hence, equal access to them is …

Background Immune checkpoint inhibitors are a standard treatment for advanced lung cancer,
although it remains important to identify biomarkers that can accurately predict treatment …

Background Currently, anticancer immunotherapy based on PD‐1/PD‐L1 blockade with
immune checkpoint inhibitors (ICIs) is being used as a standard therapy for non‐small cell lung …